[Preprint] Among individuals with prior SARS-CoV-2 infection in Brazil, vaccine effectiveness against hospitalization or death after vaccine series completion was 81.3% for CoronaVac, 89.9% for AstraZeneca, 57.7% for J&J, and 89.7% for Pfizer.

Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among – medRxiv

[In Portuguese] Commentary from one of the authors on Twitter (thread – click for more)

Já tive COVID, devo me vacinar?

Sim, sem dúvida. Como já dizíamos, agora com dados. Mostramos (preprint) que o ganho em proteção é muito grande. Para hospitalizações/óbito, após 2a dose:

➡️ 89.7% Pfizer
➡️ 89.9% AstraZeneca
➡️ 81.3% CoronaVac

Vacine-sehttps://t.co/Gzcb3cjirX pic.twitter.com/TRET1VQqQE

— Otavio Ranzani (@otavio_ranzani) December 29, 2021